[Therapeutic effect of vitamin D supplementation in mexican patients with allergic rhinitis].

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

To evaluate the impact of cholecalciferol (D₃) supplementation using clinical and paraclinical variables in patients with RA and vitamin D insufficiency and deficiency.

Who Took Part

PubMed indexes the participants as young children, children, teenagers, young adults and adults, both men and women.

A randomized, double-blind, placebo-controlled study included patients from 5 to 40 years with a diagnosis of RA and vitamin D insufficiency and deficiency.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

Topics PubMed links to this paper include Mexico, Cholecalciferol, Vitamin D Deficiency, Dietary Supplements, Rhinitis, Allergic, Vitamins and Vitamin D.

Author keywords: Allergic rhinitis, Placebo and Supplementation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)), a journal based in Mexico.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.